Global Bio-Therapeutic Glycoproteins Market Growth 2023-2029

Global Bio-Therapeutic Glycoproteins Market Growth 2023-2029

Bio-Therapeutic Glycoproteins are bioactive compounds with carbohydrates attached to proteins. Glycan is the specific site where carbohydrate attaches to proteins and process of production is called glycosylation. Bio-therapeutic glycoproteins produced with glycan moieties that are similar to natural mammal glycans. The most common types are glycosylation O-linked and N-linked that are mainly depends on protein sequence attachment. Carbohydrates linked to proteins through either α and β linkages. Glycosylation is an important process of bio-therapeutic glycoproteins because it is critically modulated into bioactivity, stability, solubility against proteolysis, yield, clearance rate from circulation and immunogenicity. The bio-therapeutic glycoproteins mainly produced by yeast expression systems, insect cells, mammalian systems, and plant-based expression systems. In yeast expression systems, yeast is cultured chemically to scale up fermentation to an industrial level. Yeast and human share same N-glycan's linkage. Insect cells represent an alternative system for expression of recombinant bio-therapeutic proteins. Later recombinant proteins are separated from insect cells. Mammalian Systems are used to produce complex bio-therapeutic glycoproteins. Most of the FDA approved bio-therapeutic glycoproteins derived from mammalian systems. Plant-based expression systems used for the scale-up production of glycoproteins. Among all systems, mammalian systems are well established in pharmaceuticals. Some examples of bio-therapeutic glycoproteins include tocilizumab, bevacizumab, adalimumab, etc.

LPI (LP Information)' newest research report, the “Bio-Therapeutic Glycoproteins Industry Forecast” looks at past sales and reviews total world Bio-Therapeutic Glycoproteins sales in 2022, providing a comprehensive analysis by region and market sector of projected Bio-Therapeutic Glycoproteins sales for 2023 through 2029. With Bio-Therapeutic Glycoproteins sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bio-Therapeutic Glycoproteins industry.

This Insight Report provides a comprehensive analysis of the global Bio-Therapeutic Glycoproteins landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bio-Therapeutic Glycoproteins portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Bio-Therapeutic Glycoproteins market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bio-Therapeutic Glycoproteins and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bio-Therapeutic Glycoproteins.

The global Bio-Therapeutic Glycoproteins market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

The potential benefits of Bio-Therapeutic Glycoproteins have been a subject of rising industrial interest in the context of wide range application. So, far they include several protein classes like antisera, cytokines, clotting factors, hormones, enzymes and enzyme inhibitors have been best suited physiologically. The trend of industrial developments likely continues alongside with growing knowledge about the functions of bio-therapeutic glycoproteins. Bio-Therapeutic Glycoproteins are a fastest growing field in the pharmaceutical industry due to a wide range of applicability. The mammalian expression system is used to produce glycoproteins that coded with human-like glycans. Bio-Therapeutic glycoproteins represent an integrated treatment for most of the autoimmune disorders, cancers, replacement therapies like hormone and enzyme substituted. All these benefits of glycoproteins drive the robust growth of the Bio-Therapeutic Glycoproteins market.

This report presents a comprehensive overview, market shares, and growth opportunities of Bio-Therapeutic Glycoproteins market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Antisera
Cytokines
Clotting Factors
Hormones
Enzymes
Enzyme Inhibitors

Segmentation by application
Oncology and Haematology
Diabetes
Cardiology
Inflammatory Diseases
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Genentech
Hoffmann-La Roche
Genzyme Corp
Abbott Laboratories
Amgen
Biogen
Merck
GlaxoSmithKline
Novartis Pharmaceuticals Corp

Key Questions Addressed in this Report

What is the 10-year outlook for the global Bio-Therapeutic Glycoproteins market?

What factors are driving Bio-Therapeutic Glycoproteins market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Bio-Therapeutic Glycoproteins market opportunities vary by end market size?

How does Bio-Therapeutic Glycoproteins break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.